MAP2K7 and melanoma: Combined targeted inhibition of mutated BRAF and downstream MEK kinases, or alternatively immune checkpoint inhibition, currently provide good therapeutic options for the systemic treatment of melanoma, offering a long-term survival to ~30% of the patients.